GlassScriptPhysician profile
Michael Lynn Partin
NPI 1427090232
$8,935.65
in general payments reported to CMS, 2019-2025
23 companies · $854 in 2025
The $854 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $1,161 · 2021: $1,658 · 2022: $1,304 · 2023: $1,492 · 2024: $1,432 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,777.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,213.19 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $1,200.95 | 2019-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $1,192.24 | 2019-2024 | Xarelto |
| Amgen INC. | $844.17 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $765.38 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $763.39 | 2021-2025 | Verquvo |
| Pfizer INC. | $735.78 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $615.17 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $497.30 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $176.67 | 2021-2022 | |
| Abbott Laboratories | $149.27 | 2023-2024 | Cardiomems, Mitraclip, Diamondback Coronary |
| Sanofi-Aventis U.S. LLC | $139.53 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $104.69 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $91.53 | 2023 | Arcalyst |
| Boston Scientific Corporation | $90.92 | 2022-2025 | Bodyguardian, Ekosonic |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $80.14 | 2021-2022 | |
| Irhythm Technologies, INC. | $71.36 | 2023 | Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $52.05 | 2022-2025 | |
| Novo Nordisk INC | $47.87 | 2024-2025 | Wegovy |
| Vifor Pharma, INC. | $40.99 | 2019 | |
| Kestra Medical Technology Services, INC. | $25.53 | 2023 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $23.01 | 2019-2020 | |
| Chiesi USA, INC. | $14.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Partin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.